Medindia LOGIN REGISTER
Medindia
Advertisement

Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)

Saturday, June 14, 2008 General News
Advertisement
VANCOUVER, June 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medicaldevice company, today announced the market launch of Quill(TM) SRSMONODERM(TM). The product will be available immediately for distribution andsale in the U.S. and Europe.
Advertisement

Quill(TM) SRS MONODERM(TM), which is made from a rapidly resorbingpolymer, is intended primarily for superficial wound closure applications andindicated for soft tissue approximation where use of an absorbable suture isappropriate.
Advertisement

"The launch of MONODERM(TM) is another example of the progress we havemade in expanding the Quill(TM) SRS product line," said Dr. William Hunter,President and CEO of Angiotech. "MONODERM(TM) is intended primarily for skinclosure and will complement Quill(TM) SRS which currently targets deeperlayers of wound closure."

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based onhistorical fact, including without limitation statements containing the words"believes," "may," "plans," "will," "estimate," "continue," "anticipates,""intends," "expects" and similar expressions, constitute "forward-lookingstatements" within the meaning of the U.S. Private Securities LitigationReform Act of 1995 and constitute "forward-looking information" within themeaning of applicable Canadian securities laws. All such statements are madepursuant to the "safe harbor" provisions of applicable securities legislation.Forward-looking statements may involve, but are not limited to, comments withrespect to our strategies or future actions, our targets, expectations for ourfinancial condition and the results of, or outlook for, our operations,research development and product and drug development. Such forward-lookingstatements involve known and unknown risks, uncertainties and other factorsthat may cause the actual results, events or developments to be materiallydifferent from any future results, events or developments expressed or impliedby such forward-looking statements. Many such risks, uncertainties and otherfactors are taken into account as part of our assumptions underlying theseforward-looking statements and include, among others, the following: generaleconomic and business conditions, both nationally and in the regions in whichwe operate; market demand; technological changes that could impact ourexisting products or our ability to develop and commercialize future products;competition; existing governmental regulations and changes in, or the failureto comply with, governmental regulations; adverse results or unexpected delaysin drug discovery and clinical development processes; decisions, and thetiming of decisions, made by health regulatory agencies regarding approval ofour technology and products; the requirement for substantial funding toconduct research and development, to expand commercialization activities orconsummate acquisitions or to service or repay debt obligations; the accuracyof our estimations of the size of the market, and the potential market, forour products in specific disease areas; sales numbers and future guidancepublicly provided by Boston Scientific Corporation regarding sales of theirpaclitaxel-eluting coronary stent products; and any other factors that mayaffect performance. In addition, our business is subject to certain operatingrisks that may cause the actual results expressed or implied by theforward-looking statements in this report to differ materially from our actualresults. These operating risks include: our ability to attract and retainqualified personnel; our ability to successfully complete preclinical andclinical development of our products; changes in business strategy ordevelopment plans; our failure to obtain patent protection for discoveries;loss of patent protection resulting from third party challenges to ourpate
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close